| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[file:Cigarettes vs Pouches.png|center]] | |||
<br> | |||
'''<big>This page is for referencing the possible benefits of Smokeless tobacco - Pouches (not Snus) AND tobacco free nicotine pouches.</big>''' | |||
=Tobacco Free Nicotine Pouches - Studies, Surveys, Papers= | =Tobacco Free Nicotine Pouches - Studies, Surveys, Papers= | ||
| Line 15: | Line 10: | ||
**Citation: Nargiz Travis, Kenneth E Warner, Maciej L Goniewicz, Hayoung Oh, Radhika Ranganathan, Rafael Meza, Jamie Hartmann-Boyce, David T Levy, The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review, Nicotine & Tobacco Research, 2024;, ntae131, https://doi.org/10.1093/ntr/ntae131 | **Citation: Nargiz Travis, Kenneth E Warner, Maciej L Goniewicz, Hayoung Oh, Radhika Ranganathan, Rafael Meza, Jamie Hartmann-Boyce, David T Levy, The Potential Impact of Oral Nicotine Pouches on Public Health: A Scoping Review, Nicotine & Tobacco Research, 2024;, ntae131, https://doi.org/10.1093/ntr/ntae131 | ||
***Acknowledgment: This work was supported by the National Cancer Institute (NCI) and Food and Drug Administration (FDA) grant U54CA229974. All authors declare no conflict of interest. MLG received a research grant from Pfizer and served as a member of the scientific advisory board of Johnson & Johnson. | ***Acknowledgment: This work was supported by the National Cancer Institute (NCI) and Food and Drug Administration (FDA) grant U54CA229974. All authors declare no conflict of interest. MLG received a research grant from Pfizer and served as a member of the scientific advisory board of Johnson & Johnson. | ||
===2024: [https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae047/7623369 Using pod based e-cigarettes and nicotine pouches to reduce harm for adults with low socioeconomic status who smoke: A pilot randomized controlled trial]=== | |||
*This study provides novel evidence that e-cigarettes and nicotine pouches can be a harm reduction tool for individuals with lower SES who smoke and are not willing to quit smoking, contributing to reducing tobacco-related disparities in this population. | |||
**Citation: Avila JC, Maglalang DD, Nollen N, Lee SC, Suh R, Malone M, Binjrajka U, Ahluwalia JS. Using pod based e-cigarettes and nicotine pouches to reduce harm for adults with low socioeconomic status who smoke: A pilot randomized controlled trial. Nicotine Tob Res. 2024 Mar 6:ntae047. doi: 10.1093/ntr/ntae047. Epub ahead of print. PMID: 38447095. | |||
***Acknowledgment: Funding and COI paywalled | |||
===2024 [https://pubmed.ncbi.nlm.nih.gov/38713545/ Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial]=== | |||
*"Implications: Little is known about the effects of racemic (vs. S-) nicotine in humans. In a sample of adults who smoke cigarettes, we identified that oral nicotine pouches containing racemic nicotine exposed participants to less nicotine than oral nicotine pouches containing only S-nicotine, but both types of oral nicotine pouches held similar, moderate appeal. Additional research evaluating the roles that flavorings, total nicotine concentration, and freebase nicotine play in the abuse liability of oral nicotine pouches would inform comprehensive product regulations to support public health." | |||
**Citation: Keller-Hamilton B, Curran H, Alalwan M, Hinton A, Brinkman MC, El-Hellani A, Wagener TL, Chrzan K, Atkinson L, Suraapaneni S, Mays D. Evaluating the Role of Nicotine Stereoisomer on Nicotine Pouch Abuse Liability: A Randomized Crossover Trial. Nicotine Tob Res. 2024 May 7:ntae079. doi: 10.1093/ntr/ntae079. Epub ahead of print. PMID: 38713545. | |||
***Acknowledgment: Grants: U54CA287392/DA/NIDA NIH HHS/United States, CA/NCI NIH HHS/United States | |||
===2024 [https://pubmed.ncbi.nlm.nih.gov/37964431/ Evaluating the effects of nicotine concentration on the appeal and nicotine delivery of oral nicotine pouches among rural and Appalachian adults who smoke cigarettes: A randomized cross-over study]=== | |||
*"Conclusions: Among adult smokers, using 6-mg nicotine concentration oral nicotine pouches (ONPs) was associated with greater plasma nicotine delivery at 30 minutes than 3-mg ONPs or cigarettes, but neither ONP relieved craving symptoms at 5 minutes as strongly as a cigarette. Accelerating the speed of nicotine delivery in ONPs might increase their misuse liability relative to cigarettes." | |||
**Citation: Keller-Hamilton B, Alalwan MA, Curran H, Hinton A, Long L, Chrzan K, Wagener TL, Atkinson L, Suraapaneni S, Mays D. Evaluating the effects of nicotine concentration on the appeal and nicotine delivery of oral nicotine pouches among rural and Appalachian adults who smoke cigarettes: A randomized cross-over study. Addiction. 2024 Mar;119(3):464-475. doi: 10.1111/add.16355. Epub 2023 Nov 14. PMID: 37964431; PMCID: PMC10872395. | |||
***Acknowledgment: This study was funded by the Addiction Innovation Fund at The Ohio State University's College of Public Health. This research was also partially supported by The Ohio State University Comprehensive Cancer Center—The James and the National Cancer Institute of the National Institutes of Health (grant number P30CA016058). BKH was supported by grant number K01DA055696 from the National Institute on Drug Abuse. BKH, AH, TLW, and DM were supported by grant number U54CA287392 from the National Cancer Institute. The sponsors had no role in the study design; in the collection, analysis or interpretation of the data; in the writing of the report; or in the decision to submit the manuscript for publication. | |||
===2023: [https://www.nature.com/articles/s41415-023-6383-7 Nicotine pouches: a review for the dental team]=== | ===2023: [https://www.nature.com/articles/s41415-023-6383-7 Nicotine pouches: a review for the dental team]=== | ||
| Line 59: | Line 69: | ||
*For the first time, U.S. health regulators have judged a type of smokeless tobacco to be less harmful than cigarettes, a decision that could open the door to other less risky options for smokers. The milestone announcement on Tuesday makes Swedish Match tobacco pouches the first so-called reduced-risk tobacco product ever sanctioned by the Food and Drug Administration. | *For the first time, U.S. health regulators have judged a type of smokeless tobacco to be less harmful than cigarettes, a decision that could open the door to other less risky options for smokers. The milestone announcement on Tuesday makes Swedish Match tobacco pouches the first so-called reduced-risk tobacco product ever sanctioned by the Food and Drug Administration. | ||
*FDA Press Release: [https://www.fda.gov/news-events/press-announcements/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products FDA grants first-ever modified risk orders to eight smokeless tobacco products] | *FDA Press Release: [https://www.fda.gov/news-events/press-announcements/fda-grants-first-ever-modified-risk-orders-eight-smokeless-tobacco-products FDA grants first-ever modified risk orders to eight smokeless tobacco products] | ||
=Tobacco Pouches - Studies, Surveys, Papers= | |||
*Please see [[SLT]] (Smokeless Tobacco) page for more details | |||
=Suggested studies to add to this page= | =Suggested studies to add to this page= | ||
[[Category:Studies, Surveys, and Papers]] | [[Category:Studies, Surveys, and Papers]] | ||
edits